Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ASN 2026
Effects of Finerenone on Kidney and Cardiovascular Outcomes in Patients with CKD and Type 1 Diabetes: An Analysis from FINE-ONE and FIDELITY
- In the FIDELITY-matched population, finerenone slowed the rate of kidney disease progression and reduced kidney and CV outcome risk versus placebo
- These data suggest that UACR reduction with finerenone is likely to lead to long-term kidney and CV benefits in patients with T1D and CKD, as seen in matched patients with T2D and CKD
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
